New research confirms that iodinated contrast agents, such as Omnipaque, do not affect ADAMTS13 activity testing, critical for diagnosing thrombotic thrombocytopenic purpura (TTP). The study tested Omnipaque's interference with a specific fluorescence-based assay and found no impact on enzyme function or fluorophore detection, even at high concentrations and with light exposure. These findings support the timely testing of ADAMTS13 activity following contrast administration for suspected TTP cases.

Source: American Journal of Clinical Pathology